Wave Life Sciences Inc. (WVE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, WVE carries an RQD Score of 22 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 5 / 20. Per the RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, the core issue is that the business is not currently converting capital into positive returns or free cash flow, so the stock's valuation rests on future outcomes not yet visible in reported results.
• Whale / 13F Flow: 5 / 20. Per the RQD rating, institutional accumulation and options positioning score weakly. Ownership detail is not provided in the holders section (see Analyst View below), so the scoring cannot be traced to specific holders.
• Insider Conviction: 3 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scores low. Insider signaling is therefore a weak support for the thesis.
• Macro Regime Fit: 7 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity. The stock is assessed as moving in line with the market, offering no defensive cushion.
• Forensic Balance Sheet: 2 / 20. Per the RQD rating, Altman Z is 0.85, Piotroski F is 2/9, and Debt/Equity is 0.5. This is the weakest pillar and the most direct flag of financial-distress risk.

Taken together, the pillars point to an investment profile where upside would depend on a substantial improvement in operating performance, while the current forensic and cash-generation metrics raise the bar for valuation support. The valuation tradeoff is that a low share price (currently $3.63) does not by itself indicate cheapness when operating margin is -60% and ROIC is -35%. Educationally, a prospective investor would weigh whether the balance sheet can fund the path to profitability before any operating turnaround becomes visible in the reported financials.

Wave Life Sciences Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the SEC financials, the company reported revenue of $42.7M in FY 2025, down from $108.3M in FY 2024. The source data does not describe the specific products or services sold, the customer base, or the revenue model beyond the sector and industry classification.

Per the SEC financials, the company has reported operating losses in each period shown, with operating income of $-215.4M in FY 2025. Per the market data, the operating margin and net margin are both -60%, the gross margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.85 and the Piotroski F-Score is 2/9. Per the SEC financials, cash rose to $602.1M in FY 2025 from $302.1M in FY 2024, while debt is reported as N/A in each period.

Per the recent news wire, the items are as follows:

• Stock Fair Value Moves Lower (CATALYST, GREEN): Headline states analysts cut growth views.
• Q3 Results Ease Loss Fears (RISK WATCH, RED): Headline reports the stock rallied after Q3 results.
• Oppenheimer Price Target Cut (RISK WATCH, RED): Headline reports a target reduction on a model update.
• Analyst Forecast & Predictions (MARKET WIRE, YELLOW): General forecast coverage.
• Director Equity Grant (MARKET WIRE, YELLOW): Headline reports a director received 10,700 stock units and a 64,000-share option.
• Strong Q3 Cash Position, RNA Pipeline (MARKET WIRE, YELLOW): Headline reports a strong cash position and pipeline advancement.

Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded. The news wire therefore reflects a mix of analyst target changes and a cash-position narrative, with the mix of catalysts and risk-watch items unresolved by the source data.

Per the Butterfly Supply-Chain Graph, the supply_chain field is NONE and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are therefore not available in source data beyond the sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations).

• What specific products, programs, or partnerships generate the reported FY 2025 revenue of $42.7M, and how much of it is recurring?
• What is the debt position behind the Debt/Equity ratio of 0.5, given that debt is reported as N/A in all periods?
• What is the cash runway implied by FY 2025 cash of $602.1M against FY 2025 free cash flow of $-188.2M?
• Why does the source data carry EPS and valuation multiples as N/A or unavailable, and what is the share count basis?
• What analyst consensus and institutional holdings exist, given that the analyst and holders sections are empty?